Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma (ORIGIN Study)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Rate of progression to multiple myeloma (MM)
研究概览
简要总结
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.
详细描述
PRIMARY OBJECTIVE:
I. To determine the rate of progression to multiple myeloma after 3 years of follow up.
SECONDARY OBJECTIVES:
I. To describe baseline patient characteristics and clinical variables. II. To identify molecular and genetic correlates that may predict for progression to multiple myeloma (MM).
OUTLINE:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with monoclonal gammopathy of unknown significance. Both criteria must be met:
- •Serum monoclonal protein < 3 g/dL or urinary monoclonal protein < 500 mg per 24 hours and clonal bone marrow plasma cells < 10%
- •Absence of myeloma defining events or amyloidosis
- •Patients with smoldering multiple myeloma. Both criteria must be met:
- •Serum monoclonal protein >= 3 g/dL or urinary monoclonal protein >= 500 mg per 24 hours and/or clonal bone marrow plasma cells 10-60%
- •Absence of myeloma defining events or amyloidosis
排除标准
- •Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least one of the following
- •Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL)
- •Renal Insufficiency: creatinine clearance < 40 ml/min or serum creatinine > 2 mg/dL
- •Anemia: hemoglobin value < 10 g/dL or 2 g/dL < normal reference
- •Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography CT (PET-CT)
- •Clonal bone marrow plasma cell percentage >= 60%
- •Involved:uninvolved serum free light chain ratio >= 100 measured by Freelite assay (The Binding Site Group, Birmingham, United Kingdom [UK])
- •> 1 focal lesions on magnetic resonance imaging (MRI) studies (each focal lesion must be 5 mm or more in size)
- •Prior or concurrent systemic treatment for asymptomatic monoclonal gammopathies
- •Bisphosphonates are permitted
- •Radiotherapy is not permitted
- •Prior treatment with chemotherapy or investigational agents for asymptomatic gammopathies is not permitted
- •Plasma cell leukemia
- •Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness/social situations that would compromise compliance with study requirements
研究组 & 干预措施
Observational (biospecimen collection)
Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.
干预措施: Biospecimen Collection (Procedure)
Observational (biospecimen collection)
Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.
干预措施: Laboratory Biomarker Analysis (Other)
结局指标
主要结局
Rate of progression to multiple myeloma (MM)
时间窗: 3 years
Kaplan-Meier method will be used to estimate time to MM progression. Log-rank test will be used to evaluate the difference in rate of progression between/among patient groups.
Progression free survival
时间窗: 3 years
Will be estimated using the Kaplan-Meier method. Log-rank test will be used to evaluate the difference in rate of progression free survival between/among patient groups.
Overall survival
时间窗: 3 years
Will be estimated using the Kaplan-Meier method. Log-rank test will be used to evaluate the difference in rate of overall survival between/among patient groups.
次要结局
- Molecular and genetic profile analysis(3 years)
- Baseline patient characteristics and clinical variables(Baseline)